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Bone morphogenetic proteins (BMP), belonging to the transforming growth factor- 
superfamily, are multifunctional regulators of cell proliferation, differentiation, and 
apoptosis in various types of malignant cells.  In this study, we investigated BMP-6 
promoter methylation in patients with various types of leukemias.  The BMP-6 
methylation was found preferentially in adult T-cell leukemia (ATL) (49 of 60, 82%) 
compared with other types of leukemias studied including acute myeloid leukemia (3 of 
67, 5%), acute lymphoblastic leukemia (6 of 38, 16%), and chronic lymphocytic 
leukemia (1 of 21, 5%).  Among subtypes of ATL, the BMP-6 gene was more frequently 
methylated in aggressive ATL forms of acute (96%) and lymphoma (94%) types than 
less malignant chronic ATL (44%) and smoldering ATL (20%).  We also analyzed the 
methylation status of peripheral blood mononuclear cells from healthy donors and 
non-malignant lymph nodes with reactive lymphadenopathy, none of which showed 
detectable BMP-6 methylation in this study.  The BMP-6 methyaltion was correlated 
with decreased mRNA transcript and protein expression.  Expression of BMP-6 was 
restored by the demethylating agent 5-aza-2’-deoxycytidine, suggesting that methylation 
was associated with the transcriptional silencing.  Serial analysis demonstrated an 
increasing methylation of CpG sites in the BMP-6 promoter and the resultant 
suppression of BMP-6 expression as ATL progressed.  These findings suggested that 
BMP-6 promoter methylation is likely to be a common epigenetic event at later stages of 
ATL and that the methylation profiles may be useful for the staging of ATL as well as for 
evaluation of the individual risk of developing the disease. 
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Introduction 
 Adult T-cell leukemia (ATL) is a highly aggressive lymphoproliferative malignancy of 
helper T lymphocytes and is etiologically linked to human T-cell leukemia virus type I 
(HTLV-I).1,2  After a latency period of decades, a small proportion of carriers (~5%) 
develops ATL.  Among subtypes of ATL, smoldering and chronic ATL are considered to be 
low-grade malignancies because of their indolent clinical courses, although they frequently 
progress to acute or lymphoma-type ATL with aggressive clinical behaviors after several 
years.3  It has been thought that the HTLV-I-mediated T-cell transformation arises from a 
multistep oncogenic process and that additional factors other than viral proteins are involved 
in leukemogenesis of ATL.4  In fact, although host genetic changes such as mutation of TP53 
5-7and Fas,8,9 or deletion of CDKN2A,10,11 CDKN2B10 and KIP112 were reported in ATL, they 
were predominantly observed in aggressive forms of ATL including acute and lymphoma 
types.  In addition to the genetic alterations, gene silencing by DNA methylation has been 
reported in a few genes encoding proteins with functions in cell growth control and 
apoptosis,13,14 suggesting that epigenetic changes were also implicated in the leukemogenesis.  
Thus, identification of genes that are preferentially methylated in ATL would be potentially 
useful for several reasons: first, it would help to study whether such events in genes may 
predispose the cells to neoplastic transformation.  Second, such methylation profiles would 
be useful to distinguish ATL at advanced stages from the disease at early stages.  Finally, 
change of the methylation patterns in a single patient may help in predicting progression of 
the disease. 
 Transforming growth factor- (TGF-) is a multi-functional cytokine that controls 
cellular responses including the induction of cell growth inhibition, differentiation, and 
apoptosis.15-19  These cellular responses are thought to define the role of TGF- as a tumor 
suppressor.  Although perturbation of TGF- signaling has been implicated in oncogenesis 
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of human solid tumors,15-19 the role of aberrant TGF- signaling in leukemogenesis has not 
been well delineated.  TGF- signals through ligation of the TGF- receptor type II 
(TR), which results in activation of TGF- receptor type I (TR) and leads to assembly 
of the heterodimeric receptor complex.20  The TR propagates the signal by 
phosphorylating the intracellular mediators Smad2 and Smad3 that subsequently 
hetero-oligomerize with a common partner Smad4 to enter the nucleus where transcription of 
TGF- target genes is regulated.20 
 Bone morphogenetic proteins (BMP), belonging to the members of the TGF- 
superfamily, were originally identified as molecules that induce bone and cartilage formations, 
and are now considered multifunctional cytokines.21,22  To date, over 20 BMPs have been 
characterized, and can be subdivided into several different classes.23  In various human 
malignacies, as with TGF-, BMPs are thought to be important regulators of cell 
differentiation and proliferation frequently in an inhibitory manner.  For example, loss of 
BMP-2 expression was reported in cancers of the prostate, colon and stomach.24-26  
Inactivation of BMP-3 and BMP-6 was suggested to promote development of lung cancer.27-29  
Moreover, the important role of BMP-3 silencing in the development of colorectal tumor has 
been shown.30  However, the underlying mechanism of the loss of BMPs expression in 
malignant diseases has not been well defined. 
 Of these BMPs, the BMP-6 gene came into the focus of our interest in DNA methylation 
study because the BMP-6 promoter sequence was previously identified as a target for aberrant 
DNA methylation.31  Recently, promoter methylation of the BMP-6 gene and the resultant 
gene suppression have been shown often in aggressive types of malignant lymphomas.32  
These findings prompted us to examine whether such methylation is also present in leukemia.  
The present study was designated to determine the methylation status of the BMP-6 gene in 
various types of leukemias.  We found that frequent methylation and the resultant loss of 
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BMP-6 expression in ATL, especially in acute and lymphoma types.  On the other hand, little 
methylation was observed in other types of leukemias including acute myeloid leukemia 
(AML), acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). 
 
Materials and methods 
Patients 
 Peripheral blood mononuclear cells (PBMC) or lymph nodes cells were obtained from 60 
untreated patients with various subtypes of ATL including acute (28 cases, denoted as cases 
A-1 to A-28), lymphoma (18 cases, L-1 to L-18), chronic (9 cases, C-1 to C-9), and 
smoldering (5 cases, S-1 to S-5) types.  Diagnosis was made based on the criteria proposed 
previously.3  A total of 126 PBMCs or bone marrow aspirates was also obtained at primary 
diagnosis from adult leukemia patients, including 67 AML patients (M1, 15 cases; M2, 24 
cases; M3, 9 cases; M4, 5 cases; M5, 9 cases, and M6, 5 cases), 38 ALL patients (L1, 9 cases; 
L2, 29 cases: B cell, 33 cases; T cell, 5 cases), and 21 CLL (B-cell type) patients.  The 
diagnosis of AML and ALL was based on French-American-British criteria and 
immunophenotype.  Their characterization is summarized in Table I.  Furthermore, PMBCs 
from 7 healthy donors and lymph node cells from 22 patients with reactive benign 
lymphadenopathy were tested for the presence of BMP-6 promoter methylation.  After 
obtaining consents for sample drawing and storage, they were stored at –80oC until 
processing. 
 
Methylation analysis 
 Sodium bisulfite modification of isolated genomic DNA (1 g) was performed using the 
EpiTect Bisulfite kit according to the manufacturer’s instructions (Qiagen, Valencia, CA).  
The bisulfite treatment of DNA converts unmethylated CpG sites to UpG without modifying 
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methlylated sites.  Aliquots of the bisulfite-treated DNA were amplified by polymerase chain 
reaction (PCR) in reaction mixtures containing 67 mM Tis-HCl (pH 8.8), 16.6 mM 
(NH4)2SO4, 6.7 mM MgCl2, 10 mM -mercaptoethanol, 1.25 mM each dNTP mixture, 0.5 
mM of each primer, and 1U of Ex Taq Hot Start Version polymerase (Takara, Tokyo, Japan).  
The primers were 5’-GGGGTAAATTTTATGGTGGTT-3’ (sense primer) and 
5’-CCTCAATCCTTATCTCTCATA-3’ (anti-sense primer), which gives a PCR product of 387 
base pair (bp), encompassing the BMP-6 promoter region -521 to -134 bp relative to the 
transcriptional start site (Fig. 1).  The PCR condition was 3 min at 94oC followed by 35 
cycles of 94oC for 40 sec, 56oC for 30 sec, and 72oC for 30 sec.  Combined bisulfite 
restriction analysis (COBRA) was carried out by overnight digestion of the PCR product at 
60oC with a restriction enzyme BstUI (New England BioLabs, Ipswich, MA) which has the 
recognition sequence 5’-CGCG-3’.32,33  The 387-bp amplicon contains six BstUI restriction 
sites (Fig. 1).  On full or partial digestion, digested fragments with various sizes are 
generated depending on sites of methylation of the CpG pairs.  The resultant DNA fragments 
were electrophoresed on 2.5% agarose gels and visualized by ethidium bromide staining.  
The digested fragments correspond to methyalted DNA.33 
 
Bisulfite genomic sequencing 
 The PCR products were purified with the Gel Extraction kit (Bionex, Seoul, Korea), 
cloned into pGEM-T Easy vector (Promega, Madison, WI), and transformed into Escherichia 
coli.  Plasmid DNA from the isolated clones containing the insert was purified using the 
FlexiPrep kit (GE Healthcare Bio-Sciences, Piscataway, NJ).  Six clones for each leukemia 
sample were sequenced with the pUC/M13 primer.  The DNA sequence was determined by 
using the BigDye Terminator Cycle Sequencing kit ver.1.1 (Applied Biosystems, Foster City, 
CA) and an ABI 3130 automated DNA sequencer. 
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Reverse-transcription-PCR 
 Total RNA was isolated using the Trizol reagent (Invitrogen, Carlsbad, CA) according to 
the manufacturer’s instructions.  Before RT, a total of 1 g of RNA was treated with DNase I 
(Invitrogen) to remove any DNA contaminant.  The DNase I-treated RNAs were subjected to 
reverse-transcription (RT) with ThermoScript reverse transcriptase (Invitrogen), as previously 
described.34  The cDNAs samples (equivalent to the cDNA amount from 50 ng of initial total 
RNA) were PCR-amplified, and the products were electrophoresed on 2.0 % agarose gels 
followed by ethidium bromide staining and visualization under UV light for the presence of 
DNA bands of appropriate sizes.  The sequences of the primers to amplify the BMP-6 gene 
were 5’-CGACAACAGAGTCGTAATCG-3’ and 5’-GCATTCTCCATCACAGTAATTG-3’, 
yielding a 195-bp fragment.  As a control for cDNA integrity and PCR reactions, the gene 
encoding -actin was amplified in parallel with following primers: 
5’-ACCTTCAACACCCCAGCCATG-3’ and 5’- GGCCATCTCTTGCTCGAAGTC -3’, 
giving a 309-bp fragment. 
 
Western blot analysis 
 Proteins (corresponding to 2 x 104 cells) were subjected to SDS-polyacrylamide gel 
electrophoresis (PAGE) and electrophoretically transferred onto a polyvinylidene difluoride 
membrane, as previously described.34  The filter was incubated with the mouse anti-BMP-6 
monoclonal antibody, and the second-step reaction was performed by incubation of the 
washed filter with a horseradish peroxidase-conjugated rabbit anti-mouse antibody.  Reactive 
proteins were detected by incubation of the washed filter in the enhanced chemiluminescence 
system according to the manufacturer’s instructions (GE Healthcare Bio-Sciences) followed 
by exposure to an autoradiographic film.  The -actin mAb was used in parallel to confirm 
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protein integrity and immunoblot reactions.  The BMP-6 monoclonal antibody recognized a 
molecular mass at around 64 kDa under reduced conditions, consistent with a size previously 
reported.32,35 
 
5-aza-2’-deoxycytidine treatment 
 Two ATL cell lines, MT-136 and ATL-1K37, were incubated in RPMI 1640 medium 
supplemented with 10% fetal calf serum in the presence or absence of 3 M of the 
demethylating agent 5-aza-2’-deoxycytidine (5-aza-dC; Sigma, St. Louis, MO) for 6 days.  
The cells were split on day 3 with the addition of fresh drug.  After the drug treatment, cells 
were harvested for DNA and RNA extractions. 
 
Results 
Methylation analysis of the BMP-6 gene in leukemias 
 We screened mononuclear cells of peripheral bloods or bone marrow aspirates from 
pretreated patients with various types of leukemias for the presence of promoter methylation 
of the BMP-6 gene using the COBRA method.  COBRA analysis is a well-characterized 
method for DNA methylation studies, and has been done largely before.33  Table I 
summarizes the result of methylation study for each group of leukemia.  The promoter 
methylation of the BMP-6 gene was found in 3 of 67 (5%) AML samples, 6 of 38 (16%) ALL 
samples, and 1 of 21 (5%) CLL samples.  Among methylation-positive ALL samples, 3 of 6 
(50%) had T-cell phenotype, and the methylation was found in 3 of 5 (60%) of T-cell ALL.  
Of note, higher frequency of the BMP-6 promoter methylation was found in ATL samples (49 
of 60; 82%) compared with other leukemias studied (10 of 126; 8%) (P < 0.001).  Among 
subtypes of ATL, there was a trend for more frequent methylation in aggressive ATL forms of 
acute type (27 of 28; 96%) and lymphoma type (17 of 18; 94%) than indolent forms of 
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chronic type (4 of 9; 44%) and smoldering type (1 of 5; 20%) (Table I).  Figure 2 shows 
representative results of COBRA in ATL.  Furthermore, we evaluated the methylation status 
of PBMCs from seven healthy donors and 22 non-malignant lymph nodes with reactive 
lymphadenopathy, none of which showed detectable BMP-6 promoter methylation (Table I).  
In these methylation analyses, the two lymphoma cell lines, Akata and SP-53, were employed 
in parallel as BMP-6 methylation-positive and -negative controls, respectively.  The BMP-6 
promoter of Akata cells were previously proven to be fully methylated by the bisulfate 
sequencing analysis, while SP-53 cells showed no evidence of the methylation.32 
 
Bisulfite sequencing analysis 
 To confirm the methylation at CpG sites of the BMP-6 promoter region, the ATL samples 
including 3 acute cases (A-8, A-10, and A-23), a lymphoma case (L-10), a chronic case (C-3), 
and a smoldering case (S-5) were subjected to bisulfite sequencing.  The PCR products were 
cloned into a plasmid vector, and six independent clones were sequenced.  As shown in 
Figure 3, the bisufite sequencing showed good concordance with COBRA.  In cases found to 
be highly methylated by COBRA (A-8, A-10, A-23, and L-10), extensive methylation across 
the CpG islands was seen, whereas the sample S-5 in which methylation was not be found by 
COBRA showed little methylation at CpG sites of the promoter region. 
 
Association of the BMP-6 promoter methylation with transcriptional gene silencing 
 To elucidate whether the aberrrant methylation of BMP-6 is associated with loss of 
BMP-6 expression, we analyzed expression of BMP-6 transcripts by RT-PCR with cycles that 
amplified the -actin cDNA to plateau levels.  Representative results are shown in Figure 4a.  
ATL samples with little BMP-6 promoter methylation such as smoldering and chronic types 
expressed BMP-6 mRNA transcripts, whereas samples with BMP-6 promoter methylation 
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(acute and lymphoma types) did not have detectable BMP-6 mRNAs.  These results 
suggested that the BMP-6 promoter methylation correlated with loss of BMP-6 expression. 
 We next assessed the association between this epigenetic aberration and transcriptional 
inactivation of the BMP-6 gene at the protein levels (Fig. 4b).  Western blot analysis showed 
that there was a negative correlation between the BMP-6 promoter methylation and BMP-6 
protein expression.  The highly methylated ATL samples (acute and lymphoma types) did 
not express the BMP-6 protein, whereas the exact opposite occurred in the unmethylated 
samples (for example, C-5, S-1, and S-4).  These Western blot analyses were conducted in 
parallel with Akata and SP-53 cells as controls.  Akata cells were previously demonstrated to 
have BMP-6 expression at mRNA and protein, whereas SP-53 cells showed no evidence of 
such expression.32   
 
Restoration of BMP-6 expression by the demethylation agent 
 To confirm that this loss of expression was due to the BMP-6 promoter methylation, two 
ATL cell lines MT-1 and ATL-1K were incubated in the presence or absence of the 5-aza-dC, 
and methylation status and BMP-6 mRNA expression were analyzed by COBRA and RT-PCR, 
respectively.  In this COBRA study, the proportion of methylated (M) versus unmethylated 
(U) products (digested versus undigested) was semiquantitated by using a densitometer to 
compare percent methylation between two samples before and after 5-aza-dC treatment.  The 
percent methylation was calculated as follows according to the previous report: M/(M + U) x 
100.33  Both MT-1 and ATL-1K cells had extensive promoter methylation of the BMP-6 gene, 
but treatment with 5-aza-dC led to partial demethylation (Fig. 5a).  In parallel with the 
demethylation, there was re-expression of the BMP-6 transcripts (Fig. 5b), implying that the 
methylation pattern is associated with transcriptional silencing. 
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Clinical aspects of BMP-6 promoter methylation in ATL patients 
 Chronic ATL, characterized as an indolent clinical form, later progresses to aggressive 
forms.3  Of the chronic ATL patients investigated in this study, none of four cases (C-4, -5, -6, 
and -7) completely negative for BMP-6 promoter methylation showed progression to acute 
ATL during the follow-up period (more than 3 years).  On the other hand, four (C-2, -3, -8 
and -9) of five cases with slight methylation progressed to acute or lymphoma-type ATL 
within a few years.  This may suggest that BMP-6 promoter methylation-positive cases 
tended to progress to acute crisis more shortly than methylation-negative cases.  Figure 6 
shows different patterns of the BMP-6 promoter methylation and its gene expression in cases 
(C-2 and C-8) with progression from chronic to acute ATL.  Sequential DNA samples were 
available in these two ATL patients whose percentage of ATL cells in peripheral blood varied 
from 17% to 44% in case C-2 and from 12% to 42% in case C-8.  Both case had the slightly 
methylated BMP-6 gene with detectable expression of its transcripts in the chronic stage.  
On the other hand, the level of methylation increased in the acute stage, and the BMP-6 
transcripts became undetectable. 
 
Discussion 
 BMP-6 is a member of the TGF- superfamily of signaling molecule that is thought to be 
an important negative-cell proliferation regulator inducing apoptosis in cells of various types.  
However, it is unclear to what extent BMP signaling is involved in malignant diseases.  In 
recent years, there has been considerable interest in the role of BMPs in tumorigenesis.  As 
with TGF-, it is thought that functional impairment by genetic alterations or epigenetic 
inactivation of genes involved in the BMP pathway may be associated with tumorigenesis 
and/or disease progression in several cancers.38,39  In fact, several findings demonstrated the 
tumor suppressor function of BMP-6.  First, BMP-6 inhibited proliferation of prostate cancer 
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cells by up-regulation of cyclin-dependent kinase inhibitors such as CIP1 and INK4c.40  
Overexpression of BMP-6 in murine epidermis suppressed skin tumor formation.41  Second, 
decreased expression of BMP receptor type II correlated with resistance to the 
growth-inhibitory effect of BMP-6 in renal cell carcinoma, suggesting that loss of sensitivity 
to BMP-6 is necessary to achieve the malignant phenotypes.42  Finally, epigenetic 
inactivation of BMP-6 by gene promoter methylation was suggested to promote lung tumor 
development.43  Furthermore, BMP-6 promoter methylation was observed in a subset of 
breast cancer cells.44  In the realm of hematological malignancies, BMP-6 inhibited 
proliferation and induce apoptosis of myeloma cells.45  Recently, we have reported that 
promoter methylation of the BMP-6 gene was found more often in aggressive types of 
malignant lymphomas.32 
 In this study, we analyzed methylation status of the BMP-6 promoter in 186 leukemia 
samples.  We found a significant higher frequency of the methylation in ATL (82%) than 
other types of leukemias including AML, ALL, and CLL (8%) (P < 0.001).  The findings 
indicate that the BMP-6 gene appeared to be preferentially methylated in ATL.  Of note, the 
BMP-6 gene was more frequently methylated in aggressive types of ATL (acute and 
lymphoma types; 96%) than less malignant types of ATL (chronic and smoldering types; 
36%) (P < 0.001).  Among T-cell ALL tested, 3 of 5 (60%) was positive for BMP-6 promoter 
methylation.  We also showed methyaltion of the BMP-6 gene was correlated with decreased 
mRNA transcript and protein expression.  Furthermore, the transcriptional repression was 
reversible by treatment with the demethylating agent 5-aza-dC.  Thus, these findings 
suggested that methylation was responsible for the transcriptional silencing.  Our data are, to 
the best of our knowledge, the first demonstration of epigenetic inactivation of the BMP 
family member in leukemia. 
 Although many ATL patients initially manifest growth of leukemic clones without 
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apparent clinical symptoms, most individuals in the chronic stages eventually undergo 
progression to aggressive stages.3  Among chronic ATL cases, some patients progress to the 
aggressive stages shortly, other patients show no progression for a long time.  Therefore, 
identification of the subgroup of chronic ATL patient who will progress to acute crisis shortly 
is clinically important.  Although the number of cases studied was relatively small, our data 
suggested that chronic ATL cases with BMP-6 promoter methylation had more aggressive 
clinical courses than those without methylation, which was accompanied with an increasing 
methylation as the disease progressed.  Thus, BMP-6 promoter methylation might be a 
potential new biomarker of risk prediction for progression to acute stages in chronic ATL 
patients.  Larger prospective studies are desired to confirm our findings, and we plan to 
collect sequential samples during the clinical courses of ATL patients for the prospective 
study. 
 Although TGF- is proposed to act as a potent endogenous negative regulator of 
hematopoiesis,46 its role of leukemogenesis remains largely unknown.  Wolfraim et al.47 
reported that Smad3 was an important tumor suppressor in T-cell ALL.  Using a Smad3 
deficient mouse model, they further demonstrated that the loss of Smad3 alone was 
insufficient to induce leukemia.47  However, when coupled with loss of the cyclin kinase 
inhibitor KIP1 expression, T-cell leukemogenesis was prompted in Smad3-deficient mice.47  
These results highlight the importance of TGF- signaling in T-cell leukemogenesis, although 
it is not likely that disruption of TGF- signaling alone is sufficient for the development of 
leukemia.47, 48  Thus, multistep process with accumulation of oncogenic events may be 
necessary for the development of leukemia, as proposed in ATL leukemogenesis.4  Their 
findings are interesting in respect of ATL leukemogenesis because the KIP1 gene is also 
mutated in acute type ATL, due to homozygous deletion and germline mutation.12  Moreover, 
studies showed that impairment of TGF- signaling in ATL can be caused by suppression of 
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Smad-dependent transcription responses by the HTLV-I-encoded Tax protein.49-51  Thus, 
perturbation of TGF- signaling appears to be associated with the development and 
progression of ATL.  Although at present we do not know how the BMP-6 promoter 
methylation and the resultant loss of gene expression contribute to the leukemogenesis of ATL, 
some speculations can be raised.  Since BMP signaling is thought to be similar to the 
paradigm established by TGF- signaling, it is logical to assume that impairment of genes 
involved in the BMP pathway may predispose to development of T-cell types of leukemias.  
Indeed, our results showed that promoter methylation of BMP-6 gene was observed 
predominantly in ATL and also in T-cell ALL although the number of T-cell ALL patients 
studied was relatively small.  Having evidence that TGF- exerts autocrine effects on tumor 
cells themselves,17,52  it is tempting to speculate that suppressive production of endogenous 
BMP-6 in leukemia cells may repress their own BMP oncogenic pathway.  If the reduced 
BMP-6 expression results in decrease in BMP signaling activity, it may be that this is 
important to the tumorigenic potential of aberrant BMP-6 promoter methyaltion.  The 
repression of BMP signaling may lead to reduction in their apoptotic and anti-proliferative 
effects, and likely provides the optional conditions for leukemogenesis in certain types of 
leukemias such as ATL.  A deeper understanding of the BMP signaling pathways is 
necessary for elucidating the relevance of BMPs to leukemia.   
 The present study implied that BMP-6 promoter methylation seemed to be a common 
phenomenon in advanced stages of ATL.  Besides the BMP-6 gene, DNA methylation has 
been reported for a few genes in ATL.  The CDKN2A gene, a tumor suppressor gene, was 
methylated in acute ATL (47%) or lymphoma-type ATL (73%) with less frequency in chronic 
(17%) and smoldering (17%) ATL.13  In addition, the Kruppel-like factor 4 (KLF4) gene 
encoding a cell cycle regulator and the early growth response 3 (EGR3) gene encoding a 
transcriptional factor for FasL transcription were found to be methylated with an increasing 
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methylation according to ATL progression.14  These findings taken together with our 
observation suggest that methylations of these genes may be important molecular events in 
the later stages of leukemogenesis of ATL and that the combined methylation profilings of 
such genes may provide information for the staging of ATL as well as for a more accurate 
evaluation of the individual risk of developing the disease.  In addition, the use of 
hypomethylating agents as a novel therapeutic strategy for prevention of disease progression 
in the chronic phase of ATL warrants further investigation. 
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TABLE I- PATIENT CHARACTERISTICS AND METHYLATION STATUS OF 
LEUKEMIAS 
 Leukemia type No. of  Median age Gender Median tumor No. of methylated 
 patients cells1 % (range) cases (%) 
 AML 67 48 (18-80) 41M, 26F 74 (28-92) 3 (5) 
 ALL 38 45 (14-77) 17M, 21F 80 (30-98) 6 (16) 
 B cell 33 47 (14-77) 14M, 19F 81 (38-98) 3 (9) 
 T cell 5 31 (17-60) 3M, 2F 70 (30-88) 3 (60) 
 CLL 21 67 (44-92) 13M, 8F 78 (41-89) 1 (5) 
 ATL 60 64 (36-85) 32M, 28F 50 (5-94) 49 (82) 
 Acute 28 63 (36-85) 15M, 13F 60 (18-94) 27 (96) 
 Chronic 9 62 (56-74) 4M, 5F 46 (8-71) 4 (44) 
 Smoldering 5 54 (50-58) 3M, 2F 7 (5-9) 1 (20) 
 Lymphoma 18 67 (39-84) 10M, 8F — 2 17 (94) 
1Tumor cells: blasts in peripheral blood or bone marrow for AML and ALL; and abnormal 
lymphocytes in peripheral blood for CLL and ATL. 
2For lymphoma type of ATL, tumor cells were obtained from pathological lymph nodes. 
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FIGURE 1- A map of the CpG islands in relation to the promoter of the BMP-6 gene, primer 
locations and restriction sites of BstUI.  The positions of sense and antisence primers used 
for COBRA are indicated by brackets.  The primers give a 387 bp-PCR product with 37 CpG 
binucleotides (underlined and numbered 1 to 37) and six BstUI-recognition sequences of 
5’-CGCG-3’ when the CpG site pairs are all methylated.  Arrow heads indicate the cutting 
sites of BstUI.  Horizontal arrow shows a translation start site. 
 
FIGURE 2- Representative COBRA results of the BMP-6 promoter methylation in ATL.  
The COBRA showed frequent aberrant methylation in acute and lymphoma types, but lower 
frequency in chronic and smoldering types.  The PCR products (387 bp) from 
bisulfite-treated DNA were digested with BstU I, which generated digested bands on full or 
partial digestions.  Digested fragments correspond to methyalted DNA.  Case numbers are 
shown on top.  The BMP-6 promoter of Akata cells was previously proven to be fully 
methylated by bisulfate genomic sequencing, while SP-53 cells showed no evidence of the 
methylation.32  Therefore, each experiment was conducted with Akata and SP-53 cells as 
positive and negative controls, respectively.  The presence of methyaltion (M) or 
unmethylation (U) is indicated below each sample.  Molecular size marker 
(X174/HincII-cut DNA) is shown. 
 
FIGURE 3- Methylation patterns of individual bisulfite-sequenced clones of the BMP-6 
promoter in ATL.  Genomic DNA was subjected to sodium bisulfite conversion, PCR 
amplification, cloning, and cycle sequencing.  Six clones from each sample were 
bisulfite-sequenced to obtain a representative sampling of methylation patterns.  Schematic 
depiction of the CpG islands in the BMP-6 promoter region is shown on top.  The 37 CpG 
sites analyzed are indicated by the vertical bars and numbered from left to right.  The 
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translation start site is shown by a horizontal arrow.  Methylated and unmethylated cytosines 
are shown by closed and open squares, respectively. 
 
FIGURE 4- Analysis of BMP-6 expression.  (a) Representative results of RT-PCR analysis 
for expression of BMP-6 mRNA in ATL.  Samples lacking BMP-6 methylation (smoldering 
and chronic types) expressed BMP-6 mRNAs, whereas samples with BMP-6 methylation 
(acute and lymphoma types) expressed little or no detectable BMP-6 mRNA transcripts.  
-Actin was used as a control for cDNA integrity and PCR reactions.  (b) Representative 
results of Western blot analysis for expression of BMP-6 protein in ATL.  Proteins were 
assessed by SDS-PAGE followed by blotting onto membranes and detection with the BMP-6 
mAb.  BMP-6 protein was not found in cells carrying BMP-6 promoter methylation (acute 
and lymphoma types), whereas unmethylated cells (smoldering and chronic types) expressed 
the protein.  Akata cells were previously demonstrated to have BMP-6 expression at mRNA 
and protein, whereas SP-53 cells showed no evidence of the expression.32  Each experiment 
was conducted with these cells as controls.  -Actin was used as a control for protein 
integrity and immunoblot reactions. 
 
FIGURE 5- Demethylation of the BMP-6 promoter reverses transcriptional silencing.  (a) 
COBRA for the BMP-6 promoter methylation in ATL cell lines (MT-1 and ATL-1K) that were 
incubated in the presence (+) or absence (-) of 5-aza-dC, showing partial demethylation in 
5-aza-dC-treated cells.  Restriction enzyme-undigested and digested bands were 
semiquantitated by a densitometry, and the calculated percentage of methylation is indicated 
below each lane.  Molecular size marker (X174/HincII-cut DNA) is shown.  (b) RT-PCR 
analysis showed methylation dependent restoration of BMP-6 transcripts.  -Actin was used 
as a control for cDNA integrity and quality.  Akata and SP-53 cells were employed for 
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controls for COBRA and RT-PCR analysis. 
 
FIGURE 6- Serial changes of BMP-6 promoter methylation and its gene expression in two 
cases (a and b) with progression from chronic to acute ATL.  COBRA and bisulfite genomic 
sequencing analysis showed an increasing methylation as the disease progressed.  Percent 
methylation analyzed by COBRA is shown below each lane.  For bisulfite genomic 
sequencing analysis, six clones from each sample were bisulfite-sequenced, and methylated 
and unmethylated cytosines are shown by closed and open squares, respectively.  The 
increased methylation was associated with suppression of BMP-6 expression, as shown by 
RT-PCR. 
 






